ATE300304T1 - Verwendung von xanthinederivaten zur herstellung eines arzneimittels zur behandlung oder verhütung von osteoporose - Google Patents

Verwendung von xanthinederivaten zur herstellung eines arzneimittels zur behandlung oder verhütung von osteoporose

Info

Publication number
ATE300304T1
ATE300304T1 AT01907785T AT01907785T ATE300304T1 AT E300304 T1 ATE300304 T1 AT E300304T1 AT 01907785 T AT01907785 T AT 01907785T AT 01907785 T AT01907785 T AT 01907785T AT E300304 T1 ATE300304 T1 AT E300304T1
Authority
AT
Austria
Prior art keywords
osteoporosis
prevention
treatment
production
medicinal product
Prior art date
Application number
AT01907785T
Other languages
English (en)
Inventor
Guenter Johannes Billen
Yamina Bouali
Yusuke Satoh
Jean-Paul Vevert
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE300304T1 publication Critical patent/ATE300304T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT01907785T 2000-02-15 2001-02-14 Verwendung von xanthinederivaten zur herstellung eines arzneimittels zur behandlung oder verhütung von osteoporose ATE300304T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0001846A FR2804867B1 (fr) 2000-02-15 2000-02-15 Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose
PCT/FR2001/000421 WO2001060372A2 (fr) 2000-02-15 2001-02-14 Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose

Publications (1)

Publication Number Publication Date
ATE300304T1 true ATE300304T1 (de) 2005-08-15

Family

ID=8847005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01907785T ATE300304T1 (de) 2000-02-15 2001-02-14 Verwendung von xanthinederivaten zur herstellung eines arzneimittels zur behandlung oder verhütung von osteoporose

Country Status (9)

Country Link
EP (1) EP1263444B1 (de)
AT (1) ATE300304T1 (de)
AU (1) AU2001235669A1 (de)
DE (1) DE60112253T2 (de)
DK (1) DK1263444T3 (de)
ES (1) ES2242731T3 (de)
FR (1) FR2804867B1 (de)
PT (1) PT1263444E (de)
WO (1) WO2001060372A2 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE230990T1 (de) * 1992-03-04 2003-02-15 Cell Therapeutics Inc Enantiomere hydroxylierte xanthinverbindungen
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
JPH09169665A (ja) * 1995-12-21 1997-06-30 Kenichi Miyamoto 骨粗鬆症治療剤
ATE226583T1 (de) * 1996-06-07 2002-11-15 Hoechst Ag Verwendung von theophyllinderivaten zur behandlung und propylaxe von schockzuständen, neue xanthinverbindungen und verfahren zu deren herstellung
JPH1192379A (ja) * 1997-07-24 1999-04-06 Kunio Takaoka 骨疾患の予防または治療剤

Also Published As

Publication number Publication date
ES2242731T3 (es) 2005-11-16
WO2001060372A3 (fr) 2002-04-11
FR2804867B1 (fr) 2002-09-20
DK1263444T3 (da) 2005-11-14
PT1263444E (pt) 2005-10-31
FR2804867A1 (fr) 2001-08-17
WO2001060372A2 (fr) 2001-08-23
DE60112253T2 (de) 2006-06-01
EP1263444A2 (de) 2002-12-11
DE60112253D1 (de) 2005-09-01
EP1263444B1 (de) 2005-07-27
AU2001235669A1 (en) 2001-08-27

Similar Documents

Publication Publication Date Title
UA74346C2 (uk) Похідні амінодикарбонових кислот, їх застосування та лікарський засіб
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
MY133732A (en) Sulfonylcarboxamide derivatives, process for their preparation and their use as medicines
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
NZ590128A (en) Prodrugs of HIV protease inhibitors
ATE311866T1 (de) Verwendung von r-arylpropionsäuren zur herstellung von arzneimitteln zur behandlung von erkrankungen rheumatischer natur
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
DE60123117D1 (de) Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE273006T1 (de) Verwendung von polyzyklischen thiazol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
ATE419012T1 (de) Verwendung von 2,5-dihydroxybenzolsulfonsäure- derivaten bei der herstellung eines medikaments zur verstärkung der wirkung anderer arzneimittel zur behandlung der erektilen dysfunktion
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
DE60112253D1 (de) Verwendung von xanthinederivaten zur herstellung eines arzneimittels zur behandlung oder verhütung von osteoporose
MXPA05008331A (es) Derivados de 3-(benzoilureido)-tiofeno sustituido, metodo para su produccion y uso de los mismos.
DE60106890D1 (de) Verwendung von cdp-choline zur behandlung des alkoholentzugsyndroms
NO20053876D0 (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE186640T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
YU30602A (sh) Primena 2-amino-3,4-dihidro-hinazolina za proizvodnju leka za lečenje ili profilaksu bolesti koje su prouzrokovane ishemičnim stanjima
ATE306273T1 (de) Verwendung von tiludronsäure beim geflügel zur herstellung eines arzneimittels zur prophylaxe und behandlung von osteoporose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1263444

Country of ref document: EP